Intimation of Transcript of Q1 FY 26 for the Earnings Conference Call held on July 21, 2025.
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Rossari Biotech reported Q1 FY26 revenue of Rs. 543.7 crore, up 11% YoY, driven by growth in HPPC and AHN segments. EBITDA grew 4.6% YoY to Rs. 67.9 crore with margin at 12.5% (vs 13.3% in Q1 FY25); excluding the loss-making Institutional/B2C business, adjusted EBITDA was Rs. 75 crore at 16% margin. Production was impacted by 10-12 days of intermittent shutdowns for ongoing capacity expansion at Rossari Biotech, Unitop and Tristar, with phased commissioning expected over coming quarters and 3x-4x asset turnover targeted at full utilization. Management guided 14-15% annual growth on both revenue and EBITDA, with margin expansion and operating leverage expected from FY27 onwards. Exports stood at ~Rs. 139 crore (~27-28% of revenue), and the company is setting up a small Rs. 15-20 crore formulation facility in Southeast Asia to serve as a regional hub.
Steady top-line growth and a healthy core B2B margin profile (16% adjusted) are positive, but near-term margins are under pressure from the Institutional/B2C drag and likely pass-through of lower raw material prices. Stock reaction hinges on execution of capacity ramp-up, EO supply timing, and whether the consumer business can break even by year-end as guided.